
On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ:SNY) Rezurock (belumosudil).
The French drug maker was seeking approval for Rezurock for the third-line treatment of adults and pediatric patients with chronic graft-versus-host disease (cGVHD).